ZA201403575B - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentInfo
- Publication number
- ZA201403575B ZA201403575B ZA2014/03575A ZA201403575A ZA201403575B ZA 201403575 B ZA201403575 B ZA 201403575B ZA 2014/03575 A ZA2014/03575 A ZA 2014/03575A ZA 201403575 A ZA201403575 A ZA 201403575A ZA 201403575 B ZA201403575 B ZA 201403575B
- Authority
- ZA
- South Africa
- Prior art keywords
- halofenate
- urate
- gout
- patients
- methods
- Prior art date
Links
- BJBCSGQLZQGGIQ-UHFFFAOYSA-N 2-acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)OCCNC(=O)C)OC1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-UHFFFAOYSA-N 0.000 title 1
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229950000958 halofenate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059394 WO2013066349A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201403575B true ZA201403575B (en) | 2015-11-25 |
Family
ID=48192533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/03575A ZA201403575B (en) | 2011-11-04 | 2014-05-16 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2773336A4 (en) |
| JP (1) | JP6202633B2 (en) |
| KR (1) | KR20140121383A (en) |
| CN (2) | CN104066427A (en) |
| AU (1) | AU2011380507B2 (en) |
| CA (1) | CA2859686C (en) |
| CL (1) | CL2014001155A1 (en) |
| IL (1) | IL232386A0 (en) |
| MX (1) | MX357507B (en) |
| NZ (1) | NZ624708A (en) |
| SG (1) | SG11201402032RA (en) |
| WO (1) | WO2013066349A1 (en) |
| ZA (1) | ZA201403575B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015512948A (en) * | 2012-04-13 | 2015-04-30 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and anti-inflammatory agents |
| JP6368756B2 (en) * | 2016-10-20 | 2018-08-01 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Method of treating hyperuricemia in patients suffering from gout using halofenate or halofenic acid and a second uric acid lowering drug |
| CN108014108A (en) * | 2016-11-03 | 2018-05-11 | 江苏万邦生化医药股份有限公司 | The application of lesinurad or its pharmaceutically acceptable salt in the medicine for treating or preventing Cushing syndrome is prepared |
| EP3701952A4 (en) | 2017-10-26 | 2021-06-30 | Otsuka Pharmaceutical Co., Ltd. | Inositol phosphate-containing composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| WO2011032175A1 (en) * | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
-
2011
- 2011-11-04 KR KR1020147015169A patent/KR20140121383A/en active IP Right Grant
- 2011-11-04 EP EP11875114.8A patent/EP2773336A4/en not_active Withdrawn
- 2011-11-04 AU AU2011380507A patent/AU2011380507B2/en not_active Ceased
- 2011-11-04 CA CA2859686A patent/CA2859686C/en not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059394 patent/WO2013066349A1/en active Application Filing
- 2011-11-04 JP JP2014541011A patent/JP6202633B2/en not_active Expired - Fee Related
- 2011-11-04 CN CN201180076191.4A patent/CN104066427A/en active Pending
- 2011-11-04 NZ NZ624708A patent/NZ624708A/en not_active IP Right Cessation
- 2011-11-04 MX MX2014005400A patent/MX357507B/en active IP Right Grant
- 2011-11-04 CN CN201910004813.0A patent/CN109908124A/en active Pending
- 2011-11-04 SG SG11201402032RA patent/SG11201402032RA/en unknown
-
2014
- 2014-04-30 IL IL232386A patent/IL232386A0/en unknown
- 2014-05-02 CL CL2014001155A patent/CL2014001155A1/en unknown
- 2014-05-16 ZA ZA2014/03575A patent/ZA201403575B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL232386A0 (en) | 2014-06-30 |
| CN104066427A (en) | 2014-09-24 |
| NZ624708A (en) | 2015-11-27 |
| AU2011380507B2 (en) | 2017-06-15 |
| AU2011380507A1 (en) | 2014-05-29 |
| KR20140121383A (en) | 2014-10-15 |
| EP2773336A4 (en) | 2015-06-03 |
| WO2013066349A1 (en) | 2013-05-10 |
| CA2859686A1 (en) | 2013-05-10 |
| CN109908124A (en) | 2019-06-21 |
| CL2014001155A1 (en) | 2015-01-16 |
| MX2014005400A (en) | 2015-02-12 |
| JP6202633B2 (en) | 2017-09-27 |
| JP2014532758A (en) | 2014-12-08 |
| CA2859686C (en) | 2018-09-11 |
| MX357507B (en) | 2018-07-12 |
| EP2773336A1 (en) | 2014-09-10 |
| SG11201402032RA (en) | 2014-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180780T1 (en) | Treatment of gout and hyperuricemia | |
| EP2716669A4 (en) | Surface-modifying method and elastic body with modified surface | |
| EP2627331A4 (en) | Methods for treating hyperuricemia and related diseases | |
| EP2788075A4 (en) | Device and method for reducing patient transthoracic | |
| PT3257546T (en) | Method of preparing a ready-to-use urinary catheter and a catheter assembly for use in said method | |
| IL228925A0 (en) | Benzothiazole compounds and their pharmaceutical use | |
| SG11201401811WA (en) | Method for preventing and/or treating insulin resistance | |
| PT2663864T (en) | Immunodiversity assessment method and its use | |
| ZA201307742B (en) | Method for manufacturing and utilizing ferritic-austenitic stainless steel | |
| EP2739352A4 (en) | Multi-modal electrotherapy method and apparatus | |
| PT2717692T (en) | Tetrahydrocannabinol-11-oic acids for use in treating fibrotic diseases | |
| DK2750705T3 (en) | Methods for effectively and rapidly desensitizing allergic patients | |
| PL2413718T3 (en) | Use of arachidonic acid for the reduction of the risk of insulin resistance later in life | |
| ZA201403575B (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| SG11201401272RA (en) | Method for manufacturing acrylic acid-based polymer and use for same | |
| IL232385A (en) | Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function | |
| HK1204913A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent | |
| EP2640376A4 (en) | Caffeic acid derivatives and their use in improving neuronal cell viability | |
| SG10201609202PA (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| EP2720703A4 (en) | Methods for increasing insulin sensitivity and treating diabetes | |
| EP2773261A4 (en) | Manometer for use in testing spinal region and related method | |
| EP2612861A4 (en) | Fluorinated thiazoles for use in treating cancer | |
| GB201003894D0 (en) | Inhibitors of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome | |
| GB201008519D0 (en) | Method and apparatus for restricting ectoparasite infection in fish within a fish pen | |
| EP2768536A4 (en) | Method for treating type i and type ii diabetes |